Answers are grounded in this paper and cite their sources.
Elevated level of active glucocorticoid (GC) deteriorates skin barrier function. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an NADPH-dependent enzyme converting inactive GC to active GC. Elevated active GC due to increased 11β-HSD1 expression might contribute to barrier impairment in aged skin and diabetic skin. We believe that the increase of 11β-HSD1 expression is a main cause of barrier abnormalities in diabetic skin and perform this study to elucidate the effect of a new 11β-HSD1 inhibitor. We compared it with a proven inhibitor in the cultured keratinocytes inducing typically 11β-HSD1 activation with dexamethasone treatment, UVB irradiation, and high glucose treatment, and the db/db mice as a type 2 diabetes murine model. In the cultured medium, cortisol, 11β-HSD1, and cytokines were measured. Also, in the db/db mice with a two-week application of 11β-HSD1 inhibitors, skin barrier function, HbA1c, corticosterone, 11β-HSD1, and cytokines were measured. In cultured keratinocytes, all concentrations and mRNA levels of cortisol, 11β-HSD1, and cytokines were decreased by both 11β-HSD1 inhibitors. In the db/db mice, both inhibitors improved skin barrier function and reduced serum level of HbA1c and skin expression of corticosterone, 11β-HSD1, and cytokines. A new 11β-HSD1 inhibitor, “11b-0048”, showed a significant inhibitory effect on the expression of 11β-HSD1 in keratinocytes activated by various conditions and diabetic skin.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: